Editorial - Malaria Vaccine for Children in Sudan: Commencing Midst the Gloom of War by Imad Fadl-Elmula, Rayan Khalid

Get full text

Validation of a multiplexed immunoassay for immunological analysis of pre erythrocytic malaria vaccines by L. K. Stockdale, S. Provstgaard-Morys, D. Bellamy, D. Woods, K. Rapi, A. Bajer, B. Hollingdale, O. Muñoz, S. Malik, A. V. S. Hill, K. J. Ewer

“…Abstract The primary immunological readout for clinical trials of R21/MatrixM™ malaria vaccine, is total IgG antibody specific to the central four amino acid NANP repeat region of the circumsporozoite protein. …”
Get full text

Malaria Vaccine Development: Are Bacterial Flagellin Fusion Proteins the Bridge between Mouse and Humans? by Daniel Y. Bargieri, Irene S. Soares, Fabio T. M. Costa, Catarina J. Braga, Luis C. S. Ferreira, Mauricio M. Rodrigues

“…In the past 25 years, the development of an effective malaria vaccine has become one of the biggest riddles in the biomedical sciences. …”
Get full text

Knowledge and willingness towards malaria vaccines among caregivers in Dar es Salaam, Tanzania by Felista Mwingira, Deokary Matiya, Frank Chacky

Subjects: “…Malaria vaccine willingness…”
Get full text

Recent Trends in Malaria Vaccine Research Globally: A Bibliometric Analysis From 2005 to 2022 by Muhammad Chutiyami

“…Conclusion: The last one and half decades have seen a significant increase in malaria vaccine research and citations, mainly targeting vaccine development, safety, and efficacy in Africa. …”
Get full text

Acceptability of the R21/Matrix-M malaria vaccine alongside existing malaria interventions in the trial context by Jayne Webster, Brian Greenwood, Daniel Chandramohan, Alassane Dicko, Issaka Sagara, Djibrilla Issiaka, Adrian VS Hill, Halimatou Diawara, Fatoumata Koita, Seydou Traoré, Jane Grant, Mehreen Datoo, Mala Sylla, Abdrahmane Boncane Dicko

“…Background The R21/Matrix-M malaria vaccine has been shown to provide high protective efficacy against malaria in a phase III trial, and has been recommended for use by WHO. …”
Get full text

The anti-circumsporozoite antibody response to repeated, seasonal booster doses of the malaria vaccine RTS,S/AS01E by M. Sanni Ali, Lisa Stockdale, Issaka Sagara, Issaka Zongo, Rakiswendé Serge Yerbanga, Almahamoudou Mahamar, Frédéric Nikièma, Amadou Tapily, Frédéric Sompougdou, Modibo Diarra, Duncan Bellamy, Samuel Provstgaard-Morys, Charles Zoungrana, Djibrilla Issiaka, Alassane Haro, Koualy Sanogo, Abdoul Aziz Sienou, Mahamadou Kaya, Seydou Traore, Oumar M. Dicko, Youssouf Kone, Hama Yalcouye, Ismaila Thera, Kalifa Diarra, Paul Snell, Opokua Ofori-Anyinam, Chris Ockenhouse, Cynthia Lee, Katie Ewer, Halidou Tinto, Abdoulaye Djimde, Jean-Bosco Ouedraogo, Alassane Dicko, Daniel Chandramohan, Brian Greenwood

“…Abstract The recently deployed RTS,S/AS01E malaria vaccine induces a strong antibody response to the circumsporozoite protein (CSP) on the surface of the Plasmodium falciparum sporozoite which is associated with protection. …”
Get full text

Integrating malaria vaccine and CRISPR/Cas9 gene drive: a comprehensive strategy for accelerated malaria eradication by Israel Charles Abraham, John Ehi Aboje, Bonaventure Michael Ukoaka, Kehinde Tom-Ayegunle, Maryam Amjad, Anas Abdulkader, Chinonyelum Emmanuel Agbo, Oluwatosin Ayokunle Akinruli, Taiwo Rebecca Akisanmi, Emmanuel Oyedeji Oyetola, Gbolahan Olatunji, Emmanuel Kokori, Nicholas Aderinto

“…Recent advancements, including the rollout of malaria vaccines, such as RTS,S/AS01 and R21/Matrix-M™, offer new avenues for prevention. …”
Get full text

Cost of introducing and delivering malaria vaccine (RTS,S/AS01E) in areas of seasonal malaria transmission, Mali and Burkina Faso by Jean Bosco Ouédraogo, Alassane Dicko, Ranju Baral, Clint Pecenka, Halimatou Diawara, Fadima Yaya Bocoum, Ann Levin, Cynthia Lee, Fatoumata Koita, Rosemonde Guissou, Seydou Yabré, Seydou Traoré, Winthrop Morgan

“…Our cost estimates provide useful insights for decisions regarding delivery approaches, as countries plan the malaria vaccine rollout.…”
Get full text

Acceptance and affordability of malaria vaccines: issues relating to hesitancy and willingness to pay amongst Nigerian parents of under-five children by Obi Peter Adigwe, Godspower Onavbavba

“…Abstract Background With the recent approval of the malaria vaccine by the World Health Organization, it is expected that global acceptance and subsequent uptake of the intervention can help to reduce the burden of the disease in Africa. …”
Get full text

PfCSP-ferritin nanoparticle malaria vaccine antigen formulated with aluminum-salt and CpG 1018® adjuvants: Preformulation characterization, antigen-adjuvant interactions, and mouse immunogenicity studies by John M. Hickey, Nitya Sharma, Max Fairlamb, Jennifer Doering, Yetunde Adewunmi, Katherine Prieto, Giulia Costa, Benjamin Wizel, Elena A. Levashina, Nicholas J. Mantis, Jean-Philippe Julien, Sangeeta B. Joshi, David B. Volkin

Subjects: “…Malaria vaccine…”
Get full text

Genetic diversity of Plasmodium falciparum reticulocyte binding protein homologue-5, which is a potential malaria vaccine candidate: baseline data from areas of varying malaria endemicity in Mainland Tanzania by Angelina J. Kisambale, Dativa Pereus, Salehe S. Mandai, Beatus M. Lyimo, Catherine Bakari, Gervas A. Chacha, Ruth B. Mbwambo, Ramadhan Moshi, Daniel A. Petro, Daniel P. Challe, Misago D. Seth, Rashid A. Madebe, Rule Budodo, Sijenunu Aaron, Daniel Mbwambo, Abdallah Lusasi, Stella Kajange, Samwel Lazaro, Ntuli Kapologwe, Celine I. Mandara, Deus S. Ishengoma

Subjects: Get full text

Computational design, expression, and characterization of a Plasmodium falciparum multi-epitope, multi-stage vaccine candidate (PfCTMAG) by Joan A. Chick, Nadege N. Abongdia, Robert A. Shey, Tobias O. Apinjoh

“…Malaria, a tropical disease, claims the lives of thousands of people annually and the development of resistance to insecticides and antimalarial drugs poses a great challenge to current prevention and control strategies. Current malaria vaccines are limited in efficacy, duration of protection, and safety, due to the high antigenic diversity and complex life cycle of the Plasmodium parasite. …”
Get full text

Naturally Acquired Antibody Responses to a Synthetic Malaria Antigen AS202.11 by Rebeka Nazareth, Pius Horumpende, Tolbert Sonda, Arnold Ndaro, Edson Mollel, Eliakim Paul, Emmanuel Athanase, Jaffu Chilongola

“…A major challenge to malaria vaccine development is identification of protective epitopes and respective protective immune responses. …”
Get full text

N-Terminal Plasmodium vivax Merozoite Surface Protein-1, a Potential Subunit for Malaria Vivax Vaccine by Fernanda G. Versiani, Maria E. Almeida, Luis A. Mariuba, Patricia P. Orlandi, Paulo A. Nogueira

“…The lack of in vitro cultures for P. vivax represents a major delay in developing a functional malaria vaccine. One of the major candidates to antimalarial vaccine is the merozoite surface protein-1 (MSP1), which is expressed abundantly on the merozoite surface and capable of activating the host protective immunity. …”
Get full text

A systematic review on malaria and Tuberculosis (TB) vaccine challenges in sub-Saharan African clinical trials. by Maonezi Abas Hamisi, Nur Ain Mohd Asri, Aini Syahida Mat Yassim, Rapeah Suppian

“…<h4>Results</h4>A total of 2342 articles were obtained, 50 of which met the inclusion criteria. 28 (56%) articles reported on malaria vaccine attributes, while 22 (44%) articles reported on TB vaccines. …”
Get full text

The Efforts to Implement a Malaria Elimination Strategy in The Highly Endemic Malaria Region of Papua Province, Indonesia by Erni Juwita Nelwan

“…Indonesia has recently completed a malaria vaccine trial, the IDSPZV1, which included the PfSPZ Vaccine and PfSPZ-CVac (CQ), conducted among soldiers deployed to Papua Province, New Guinea, for 10 months. …”
Get full text

Molecular Assessment of Domain I of Apical Membrane Antigen I Gene in Plasmodium falciparum: Implications in Plasmodium Invasion, Taxonomy, Vaccine Development, and Drug Discovery by Che Roland Achungu, Damian Nota Anong, Robert Adamu Shey, Cevie Jesenta Tabe

“…The creation of a universal malaria vaccine based on the AMA1 antigen is challenging due to these knowledge limitations. …”
Get full text

Subclinical Plasmodium spp. Infections in a Community Setting in Bangui, Central African Republic by Nzoumbou-Boko R, Denissio Morissi Nalingbo MCI, Yambiyo BM, Detol R, Moussa ERF, Nalinga D, Namsenei-Dankpea LJVDLG, Manirakiza A, Ayong L, Boum II Y

“…The high prevalence of community malaria demonstrates its persistence as a major public health challenge in the country, highlighting the need to intensify its ongoing control using new tools such as the upcoming malaria vaccine.Plain Language Summary: Malaria is widespread in the Central African Republic, with prevalence data based mainly on highly flawed medical records. …”
Get full text